PMID- 26487275
OWN - NLM
STAT- MEDLINE
DCOM- 20160719
LR  - 20181202
IS  - 1476-5551 (Electronic)
IS  - 0887-6924 (Linking)
VI  - 30
IP  - 3
DP  - 2016 Mar
TI  - Impact of cytogenetic classification on outcomes following early high-dose 
      therapy in multiple myeloma.
PG  - 633-9
LID - 10.1038/leu.2015.287 [doi]
AB  - Early high-dose therapy (HDT), consisting of high-dose melphalan and autologous 
      stem cell transplantation following doublet or triplet novel agent induction, is 
      a preferred management strategy for transplant-eligible myeloma patients. We set 
      out to examine the utility of the current fluorescence in situ hybridization 
      (FISH)-based risk stratification in a homogenously treated population of 
      transplant-eligible myeloma patients receiving novel induction regimens and early 
      HDT with or without posttransplant maintenance therapy. FISH was available in 409 
      patients at the time of diagnosis for patients receiving HDT within 12 months of 
      diagnosis. We present comprehensive outcomes for chromosome 14 translocations and 
      17p abnormalities that both support and refute current risk stratification 
      models. In contrast to its current classification as a marker of 'standard risk' 
      (SR), t(11;14) was associated with inferior overall survival (OS) when compared 
      with the classical SR cohort. The use of novel agent maintenance therapy 
      (bortezomib or lenalidomide) following early HDT ameliorates the negative 
      prognostic value of high-risk (HR) cytogenetic markers. HR patients who received 
      maintenance following early HDT had similar OS compared with the SR cohort at 5 
      years.
FAU - Kaufman, G P
AU  - Kaufman GP
AD  - Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
FAU - Gertz, M A
AU  - Gertz MA
AD  - Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
FAU - Dispenzieri, A
AU  - Dispenzieri A
AD  - Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
FAU - Lacy, M Q
AU  - Lacy MQ
AD  - Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
FAU - Buadi, F K
AU  - Buadi FK
AD  - Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
FAU - Dingli, D
AU  - Dingli D
AD  - Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
FAU - Hayman, S R
AU  - Hayman SR
AD  - Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
FAU - Kapoor, P
AU  - Kapoor P
AD  - Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
FAU - Lust, J A
AU  - Lust JA
AD  - Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
FAU - Russell, S
AU  - Russell S
AD  - Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
FAU - Go, R S
AU  - Go RS
AD  - Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
FAU - Hwa, Y L
AU  - Hwa YL
AD  - Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
FAU - Kyle, R A
AU  - Kyle RA
AD  - Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
FAU - Rajkumar, S V
AU  - Rajkumar SV
AD  - Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
FAU - Kumar, S K
AU  - Kumar SK
AD  - Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
LA  - eng
PT  - Journal Article
DEP - 20151021
PL  - England
TA  - Leukemia
JT  - Leukemia
JID - 8704895
RN  - 4Z8R6ORS6L (Thalidomide)
RN  - 69G8BD63PP (Bortezomib)
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - F0P408N6V4 (Lenalidomide)
RN  - Q41OR9510P (Melphalan)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Bortezomib/therapeutic use
MH  - Chromosomes, Human, Pair 11
MH  - Chromosomes, Human, Pair 14
MH  - Chromosomes, Human, Pair 17
MH  - Cytogenetic Analysis
MH  - Dexamethasone/therapeutic use
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Induction Chemotherapy/methods
MH  - Lenalidomide
MH  - Male
MH  - Melphalan/therapeutic use
MH  - Middle Aged
MH  - Multiple Myeloma/*diagnosis/genetics/mortality/*therapy
MH  - Prognosis
MH  - Remission Induction
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - Thalidomide/analogs & derivatives/therapeutic use
MH  - Translocation, Genetic
MH  - Transplantation, Autologous
MH  - Treatment Outcome
EDAT- 2015/10/22 06:00
MHDA- 2016/07/20 06:00
CRDT- 2015/10/22 06:00
PHST- 2015/05/25 00:00 [received]
PHST- 2015/09/16 00:00 [revised]
PHST- 2015/10/01 00:00 [accepted]
PHST- 2015/10/22 06:00 [entrez]
PHST- 2015/10/22 06:00 [pubmed]
PHST- 2016/07/20 06:00 [medline]
AID - leu2015287 [pii]
AID - 10.1038/leu.2015.287 [doi]
PST - ppublish
SO  - Leukemia. 2016 Mar;30(3):633-9. doi: 10.1038/leu.2015.287. Epub 2015 Oct 21.